پاورپوینت کامل The WHO Medicines Strategy 2008-2013 25 اسلاید در PowerPoint

توجه : این فایل به صورت فایل power point (پاور پوینت) ارائه میگردد

 پاورپوینت کامل The WHO Medicines Strategy 2008-2013 25 اسلاید در PowerPoint دارای ۲۵ اسلاید می باشد و دارای تنظیمات کامل در PowerPoint می باشد و آماده ارائه یا چاپ است

شما با استفاده ازاین پاورپوینت میتوانید یک ارائه بسیارعالی و با شکوهی داشته باشید و همه حاضرین با اشتیاق به مطالب شما گوش خواهند داد.

لطفا نگران مطالب داخل پاورپوینت نباشید، مطالب داخل اسلاید ها بسیار ساده و قابل درک برای شما می باشد، ما عالی بودن این فایل رو تضمین می کنیم.

توجه : در صورت  مشاهده  بهم ریختگی احتمالی در متون زیر ،دلیل ان کپی کردن این مطالب از داخل فایل می باشد و در فایل اصلی پاورپوینت کامل The WHO Medicines Strategy 2008-2013 25 اسلاید در PowerPoint،به هیچ وجه بهم ریختگی وجود ندارد

بخشی از مطالب داخلی اسلاید ها

پاورپوینت کامل The WHO Medicines Strategy 2008-2013 25 اسلاید در PowerPoint

اسلاید ۴: Trends in global pharmaceutical situation, new challenges for 2008-2013 (1)Recognition that vertical programmes need an integrated approach with horizontal health systems, supply systemsMore interest in medicine quality and quality assurance systems; this implies the need for practical global standards and support to national regulatory agenciesSeveral new global funding mechanisms for essential medicines; these need global health policy direction, global standards and technical support from WHOMore players and partnerships, complicating the landscape; these need a multi-stakeholder (MOH-plus) approach and coordination at country level

اسلاید ۵: Trends in global pharmaceutical situation, new challenges for 2008-2013 (2)IPR interest shifting from global TRIPS discussion towards technical support to countries; new focus on innovation and public health, inter-governmental processMore interest of Middle Income Countries in medicine issues such as pricing, reimbursement and quality; need for relevant standards and high-level technical supportDG priorities (PHC, Africa, women) implies the need to re-shape PHC, renewed focus on public sector and essential medicines, new focus on reimbursement schemes Recent WHA resolutions (prices, IPR, rational use, medicines for children); this implies the need for fundraising and recruitment to expand work in these areas

اسلاید ۶: Example of impact of earlier Medicine Strategies:

اسلاید ۷: Examples of country progress in supply:

اسلاید ۸: WHO Medicines Strategy 2008-2013 Strategic landscapeExperiences from 2000-03 and 2004-07 Medicine StrategiesMillennium Development Goals 2000-2015WHO Medium Term Strategic Plan 2008-2013Strategic Objective 11 covers access, quality, rational useRecent WHA resolutionsRational use, EMs for children, IGWG Strategic Plan 2008-15Stated priorities of the new Director-GeneralMDGs, Universal Access through PHC/Health Systems; evidence-based policies; partnerships; health-in-all-policies Other country needs (if not included in above)

اسلاید ۹: Strategic landscape: Medicine-related Millennium Development Goals

اسلاید ۱۰: New standard set of indicators for measuring access for WHO/MTSP, UNDP/MDG8 Gap Analysis and Lancet assessmentGovernment commitment:Access to essential medicines/technologies as part of the fulfillment of the right to health, recognized in the constitution or national legislation (S)Existence and year of a published national medicines policy (S)Rational selection:Existence and year of a published national list of essential medicines (S)Affordable prices:Legal provisions to allow generic substitution in private sector (S) Median consumer price ratio of 30 selected EMs in pub/private facilities (P)Percentage mark-up between manufacturers and consumer price (P)Sustainable financing:Public and private per capita expenditure on medicines (P)% of population covered by national health service or health insurance (P)Reliable systems:Average availability of 30 selected EMs in public/private health facilities (O)(Quantified intuition)

اسلاید ۱۱: WHO strategic directions in medicines 1: Policy, access (1)National medicine policies: Continue national policies; new focus on comprehensive PHC, health insurance; in countries more focus on strategic components of medicines policyIntellectual Property Rights: Continue technical support; new focus on IPR and innovation, new approach to medicine patentsTraditional medicine: Continue support on regulating quality and safety; new focus on integrating with allopathic medicine